Outlook Therapeutics Inc. (OTLK), a clinical-stage biopharmaceutical company, announced on Tuesday the completion of a federal dispute resolution (FDR) meeting with the U.S. Food and Drug Administration (FDA) regarding the regulatory pathway for ONS-5010/ LYTENAVA, a treatment for age related macular degeneration.
LYTENAVA (bevacizumab-vika) is an investigational, humanized monoclonal antibody developed to bind with the human vascular endothelial growth factor (VEGF) to prevent endothelial cell proliferation in neovascular age-related macular degeneration. The company had previously received a complete response letter (CRL) from the FDA in December, 2025, regarding the biologics license application (BLA) for LYTENAVA. In attending the Type A meeting with the Division of Ophthalmology and Office of Specialty Medicine, the company expects to align with the FDA in the required steps to approval.
A formal response from the FDA is anticipated for May, 2026.
OTLK is currently trading at $0.31, down 15.68%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.